G
14.76
0.56 (3.94%)
| Previous Close | 14.20 |
| Open | 14.39 |
| Volume | 575,073 |
| Avg. Volume (3M) | 843,166 |
| Market Cap | 458,284,736 |
| Price / Sales | 9.37 |
| Price / Book | 0.520 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2024 |
| Operating Margin (TTM) | -301.88% |
| Diluted EPS (TTM) | -63.54 |
| Quarterly Revenue Growth (YOY) | 26.10% |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 10.66 |
| Operating Cash Flow (TTM) | -577.16 M |
| Levered Free Cash Flow (TTM) | -298.66 M |
| Return on Assets (TTM) | -13.19% |
| Return on Equity (TTM) | -65.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | GRAIL, Inc. | Bullish | - |
AIStockmoo Score
2.5
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 13.10% |
| % Held by Institutions | 75.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Canaccord Genuity, 191.33%) | Buy |
| Median | 31.50 (113.42%) | |
| Low | 20.00 (Morgan Stanley, 35.50%) | Hold |
| Average | 31.50 (113.42%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 30.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 14 May 2025 | 43.00 (191.33%) | Buy | 32.89 |
| 21 Apr 2025 | 32.00 (116.80%) | Buy | 26.42 | |
| Morgan Stanley | 18 Mar 2025 | 20.00 (35.50%) | Hold | 28.18 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |